Connect your AI

Enovis ENOV Proceeds from issuance of shares

Proceeds from issuance of shares at other companies

MedtronicMDT

——

Other financials

Income statement

Revenue$589.2M+5.4%

Gross profit$365.5M+10.0%

Operating income$6.5M+114%

Net income-$8.8M+84.3%

EPS (diluted)-$0.15+84.7%

Balance sheet

Cash & equivalents$33.1M-13.9%

Total debt$1.4B-3.1%

Total equity$1.5B-43.6%

Total assets$3.8B-21.4%

Cash flow

Operating cash flow$24.0M+1,601%

CapEx$52.8M+22.1%

Free cash flow-$28.9M+35.7%

Valuation

Market cap$1.23B-28.4%

Enterprise value$2.55B-17.1%

P/S0.5×-0.3×

Profitability

Gross margin60.5%+4.0pp

Operating margin-47%+18.6pp

Net margin-49.9%+24.1pp

FCF margin-3.1%-1.1pp

Returns & leverage

Return on equity-55.5%-1,722pp

Debt / equity0.9×+0.4×

Current ratio2×-0.5×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOrSaleOfEquity.

The official record: Enovis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enovis's proceeds from issuance of shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Enovis's proceeds from issuance of shares?: Enovis (ENOV) reported proceeds from issuance of shares of $628K in Q1 2026.
How has Enovis's proceeds from issuance of shares changed year-over-year?: Enovis's proceeds from issuance of shares increased by 84.2% year-over-year, from $341K to $628K.